Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

It can be a shock to learn that you have a serious medical problem like wet age-related macular degeneration. Realistically, the condition is likely to disrupt your everyday life, at least for a while ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

A recent study found that the triple-layer sign (TLS) obtained on optical coherence tomography has high sensitivity and ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...